ArticlePediatric research2026
Effects of Lacticaseibacillus rhamnosus MP108 on functional constipation symptoms and gut microbiota in children.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundWe aimed to evaluate the effects of a probiotic preparation containing Lacticaseibacillus rhamnosus MP108 on the improvement of clinical symptoms and gut microbiota in children with Functional Constipation (FC).
methodsThis 4-week randomized, double-blind, placebo-controlled trial assigned 6 to 36-month-old children with FC to supplementation with Lacticaseibacillus rhamnosus MP108 (intervention group, n = 77) or maltodextrin supplementation (control group, n = 77). An electronic questionnaire was used to obtain the defecation status, and 16S rRNA sequencing technology was used to extract the characteristics of gut microbiota. The primary outcomes were treatment success rate (defined as average of ≥3 spontaneous stools movements per week), weekly defecation frequency, and stool hardness. The secondary outcomes included constipation-related symptoms and changes in the gut microbiota. The analysis was performed on an intention-to-treat basis.
resultsAfter the intervention, the treatment success rate in the intervention group was significantly higher than that in the control group (83.1% vs. 63.6%, P = 0.006). The intervention group demonstrated significantly higher weekly defecation frequency (4.99 ± 2.88 vs. 3.71 ± 2.86, P = 0.002) and Bristol Stool Form Scale (BSFS) scores (3.75 ± 1.04 vs. 2.99 ± 1.17, P = 0.002) compared to the control group. There were significant differences in the gut microbiota, and the intervention group had a higher diversity of gut microbiota Alpha (P = 0.047) and a higher relative abundance of Lacticaseibacillus, Bifidobacteriaceae, Parabacteroides_B_862066; while Erysipelatoclostridium and Eggerthella had lower relative abundance.
conclusionLacticaseibacillus rhamnosus MP108 can effectively improve some constipation symptoms and gut microbiota structure in children with FC. IMPACT: This is the first study to evaluate the effects of Lacticaseibacillus rhamnosus MP108 on Functional Constipation (FC) in children under 3 years old. The study shows that probiotics containing Lacticaseibacillus rhamnosus MP108 can improve some clinical symptoms and gut microbiota structure in children with FC. The positive results of Lacticaseibacillus rhamnosus MP108 intervention provide new insights for the treatment of FC in children.
Identifiers
41519948What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.